CRBU Stock Analysis: Caribou Biosciences | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 156m USD | 12M Return: -30.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.37M
Qual. Beats: 1
Rev. Trend: -70.2%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 4.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Caribou Biosciences, Inc. (NASDAQ: CRBU) is a clinical-stage biopharmaceutical company headquartered in Berkeley, California, focused on developing allogeneic cell therapies using its proprietary CRISPR hybrid RNA-DNA genome-editing platform. Founded in 2011, the company went public in July 2021 and currently operates as a micro-cap within the Health Care / Biotechnology sector.
The companys clinical pipeline is led by two Phase 1 allogeneic CAR-T cell therapy candidates: Vispacabtagene Regedleucel, an anti-CD19 therapy targeting relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an anti-BCMA therapy for relapsed or refractory multiple myeloma. Both programs are being evaluated in early-stage clinical trials.
Caribous business model centers on allogeneic (off-the-shelf) cell therapies, which are manufactured from healthy donor cells rather than a patients own cells, in contrast to autologous approaches. The company leverages CRISPR-based gene editing to engineer these cell therapies with the aim of producing scalable, standardized treatments for hematologic cancers and other diseases.
- CB-011 Phase 1 multiple myeloma data readout approaches
- Vispacabtagene Regedleucel Phase 1 lymphoma update due
- Cash burn raises dilution risk on micro-cap balance sheet
| Net Income: -133.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.68 > 0.02 and ΔFCF/TA -16.21 > 1.0 |
| NWC/Revenue: 916.8% < 20% (prev 1.90k%; Δ -987.1% < -1%) |
| CFO/TA -0.68 > 3% & CFO -101.3m > Net Income -133.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (95.9m) vs 12m ago 3.43% < -2% |
| Gross Margin: -123.4% > 18% (prev -528.0%; Δ 404.6% > 0.5%) |
| Asset Turnover: 5.30% > 50% (prev 3.62%; Δ 1.68% > 0%) |
| Interest Coverage Ratio: -6.16 > 6 (EBIT TTM -115.1m / Interest Expense TTM 18.7m) |
| A: 0.69 (Total Current Assets 122.4m - Total Current Liabilities 19.7m) / Total Assets 149.0m |
| B: -4.17 (Retained Earnings -621.6m / Total Assets 149.0m) |
| C: -0.54 (EBIT TTM -115.1m / Avg Total Assets 211.3m) |
| D: 2.17 (Book Value of Equity 102.0m / Total Liabilities 47.0m) |
| Altman-Z'' = -10.46 = D |
| DSRI: 0.76 (Receivables 2.36m/2.74m, Revenue 11.2m/9.92m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.32 (AQ_t 0.02 / AQ_t-1 0.07) |
| SGI: 1.13 (Revenue 11.2m / 9.92m) |
| TATA: -0.21 (NI -133.2m - CFO -101.3m) / TA 149.0m) |
| Beneish M = -3.56 (Cap -4..+1) = AAA |
As of July 28, 2026, the stock is trading at USD 1.59 with a total of 731,504 shares traded. Over the past week, the price has changed by -1.85%, over one month by -10.17%, over three months by -25.35% and over the past year by -30.57%.
Current recommended Stop Loss: 1.40 (which is 11.9% or 1.7 ATR below the current price).
Caribou Biosciences has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy CRBU.
- StrongBuy: 5
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12 | 654.7% |
P/S = 13.8993
P/B = 1.5263
Revenue TTM = 11.2m USD
EBIT TTM = -115.1m USD
EBITDA TTM = -112.0m USD
Long Term Debt = 25.7m USD (estimated: total debt 26.9m - short term 1.29m)
Short Term Debt = 1.29m USD (from shortTermDebt, last quarter)
Debt = 26.9m USD (from shortLongTermDebtTotal, last quarter) (leases 26.9m already included)
Net Debt = -90.7m USD (calculated: Debt 26.9m - CCE 117.6m)
Enterprise Value = 65.0m USD (155.7m + Debt 26.9m - CCE 117.6m)
Interest Coverage Ratio = -6.16 (Ebit TTM -115.1m / Interest Expense TTM 18.7m)
EV/FCF = -0.64x (Enterprise Value 65.0m / FCF TTM -101.6m)
FCF Yield = -156.3% (FCF TTM -101.6m / Enterprise Value 65.0m)
FCF Margin = -907.3% (FCF TTM -101.6m / Revenue TTM 11.2m)
Net Margin = -1.19k% (Net Income TTM -133.2m / Revenue TTM 11.2m)
Gross Margin = -123.4% ((Revenue TTM 11.2m - Cost of Revenue TTM 25.0m) / Revenue TTM)
Gross Margin QoQ = 72.92% (prev 82.69%)
Tobins Q-Ratio = 0.44 (Enterprise Value 65.0m / Total Assets 149.0m)
Interest Expense / Debt = 69.29% (Interest Expense 18.7m / Debt 26.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -90.9m (EBIT -115.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.22 (Total Current Assets 122.4m / Total Current Liabilities 19.7m)
Debt / Equity = 0.26 (Debt 26.9m / totalStockholderEquity, last quarter 102.0m)
Debt / EBITDA = 0.81 (negative EBITDA) (Net Debt -90.7m / EBITDA -112.0m)
Debt / FCF = 0.89 (negative FCF - burning cash) (Net Debt -90.7m / FCF TTM -101.6m)
Total Stockholder Equity = 133.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -63.04% (Net Income -133.2m / Total Assets 149.0m)
RoE = -100.1% (Net Income TTM -133.2m / Total Stockholder Equity 133.0m)
RoCE = -72.53% (EBIT -115.1m / Capital Employed (Equity 133.0m + L.T.Debt 25.7m))
RoIC = -69.92% (negative operating profit) (NOPAT -90.9m / Invested Capital 130.1m)
WACC = 12.37% (E(155.7m)/V(182.7m) * Re(14.51%) + (debt cost/tax rate unavailable))
Discount Rate = 14.51% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 97.78 | Cagr: 3.65%
[DCF] Fair Price = unknown (Cash Flow -101.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.93 | # QB: 1
Revenue Correlation: -70.18 | Revenue CAGR: -36.31% | SUE: 0.37 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.31 | Chg30d=+2.63% | Revisions=+0% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.32 | Chg30d=+0.00% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=-1.25 | Chg30d=+0.66% | Revisions=-25% | GrowthEPS=+15.1% | GrowthRev=+130.0%
EPS next Year (2027-12-31): EPS=-1.40 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=-12.3% | GrowthRev=+17.2%
[Analyst] Revisions Ratio: -40% (up=0, down=2)